COVID-19：RDIF､Sputnik V をメキシコに供給：Landsteiner Ink（動画）：
RDIF Deal for Sputnik V COVID-19 Vaccine to Mexico：
RDIF与签署了向墨西哥提供Sputnik V 疫苗的协议
2020年9月10日
RDIF：
ロシアの直接投資基金（RDIF）、2020年9月9日、明らかにしました。
「Landsteiner Scientific社と共同で、3200万回分スプートニクVワクチンを、メキシコに供給すること」で、合意したと発表しました。
これは、メキシコ全人口の約25％に相当します。
メキシコ規制当局の承認を条件として、2020年11月には、出荷開始の予定。
Landsteiner Scientific：
1998年に設立され、メキシコシティに本社を置く垂直統合された非公開の製薬会社。
According to the press release,
“As part of the agreement with RDIF, Landsteiner Scientific as a partner of RDIF would distribute the vaccine in Mexico.
On August 11,
the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiologywas registered by the Ministry of Health of Russia and became the world’s first registered vaccine against COVID-19 based on human adenoviral vectors platform.
Detailed information on the Sputnik V vaccine, the technological platform of human adenoviral vectors, and other details are available at sputnikvaccine.comOn September 4, a research paper on the results of Phase I and Phase II clinical trials of the Sputnik V vaccine
was published in one of the leading international medical journals The Lancet.
Phase I and Phase II trials :
demonstrated no serious adverse events and a stable immune response in 100% of participants.
Post-registration clinical trials of Sputnik V vaccine involving 40,000 volunteers are currently ongoing.First results of these trials :
are expected to be published in October-November 2020.
Health safety of the human adenovirus vaccines :
has been proven by more than 75 international publications and 250 clinical trials showing greater safety track record of human adenoviral vectors versus novel unproven technologies such as monkey adenoviral vectors or mRNA.”
SWFI
RDIF and Landsteiner Scientific agree to supply 32 million doses of Sputnik V vaccine to Mexico